Drug intelligence / Profile preview

EBV-Specific CTLs + CD45 monoclonal antibody

Development stage: Preclinical
Lead developer: Center for Cell and Gene Therapy
Modality: Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EBV-Specific CTLs + CD45 monoclonal antibody is a combination therapy that pairs Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes with an anti-CD45 monoclonal antibody. The CD45 component targets the leukocyte common antigen (LCA), which is expressed by all nucleated hematopoietic cells excluding mature erythrocytes and platelets. CD45 is a receptor-type protein tyrosine phosphatase that plays an important role in lymphocyte activation and development. The anti-CD45 antibody component can be used to deliver targeted radiation to hematopoietic tissues while sparing normal organs, making it particularly useful in treating hematologic malignancies like leukemia. The EBV-specific CTLs provide an immunotherapeutic approach targeting EBV-associated malignancies.

Targets

PTPRC (Receptor-type tyrosine-protein phosphatase C)

Beyond the preview

Go deeper on EBV-Specific CTLs + CD45 monoclonal antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBV-Specific CTLs + CD45 monoclonal antibody.